At the Maiani hospital in Tigray in the far north of Ethiopia, Kiros Girmay, a 60-year-old ex-soldier, looks despairingly at the dirty sheets on his bed.

Nomlabofusp program update expected mid-December to include available safety, pharmacokinetic (PK) and frataxin data, as well as available ...

Achieved $20.1 million in OJEMDATM (tovorafenib) net product revenueEnded the third quarter with $558.4 million in cash, cash equivalents and ...

Novartis AG's revenue and core EPS topped analysts' expectations in Q3. Click here to read more on the analysis of NVS stock ...

Bright Minds Biosciences' BMB-101 shows promise in treating drug-resistant epilepsy. Read why DRUG stock is a strong ...

My name is Julianne, and I will be your conference facilitator today for Amgen's third quarter 2024 financial results ...

Omnicell delivers solid third quarter financial results. Total revenues of $282 million. GAAP net income per diluted share of $0.19. Non-GAAP net income per diluted share of $0.56 ...

Blueprint Medicines Corporation today reported financial results, provided a business update for the third quarter ended Sept 30, 2024, and ...

Cabozantinib is the active ingredient in two of Exelixis' three approved drugs (Cabometyx and Cometriq) and its strongest US patent covering cabozantinib’s composition of matter expires in 2030.

Jeffrey Dayno; President, Chief Executive Officer, Director; Harmony Biosciences Holdings Inc Jeffrey Dierks; Chief Commercial Officer; Harmony Biosciences Holdings Inc Kumar Budur; Chief Scientific ...

UPPSALA, SWEDEN / ACCESSWIRE / October 30, 2024 / Senzime (STO:SEZI)(OTCQX:SNZZF) invites investors, analysts, and media to a webcast presentation of the third quarter report for 2024 on November 6, 1 ...

Learn expert tips for investing in equities and outperforming the market. Discover strategies for long-term growth, building ...